

NTI164 to be presented at International Rett Syndrome Foundation Annual Scientific Meeting

Neurotech International Limited (ASX: NTI) (“Neurotech” or “the Company”), a clinical-stage biopharmaceutical company focused on paediatric neurological disorders, is pleased to announce that its lead product NTI164 will be highlighted in presentations at the upcoming International Rett Syndrome Foundation (IRSF) Scientific Meeting.

The event is being held 9-11 June 2025 in Boston, USA with attendees representing academia, industry, and governmental agencies present emerging data and insights about the most pressing issues surrounding Rett Syndrome.

Neurotech's Principal Investigator for the Rett Study, Professor Carolyn Ellaway, will be in attendance to deliver both an oral and poster presentation regarding NTI164.

The poster, titled 'A novel full-spectrum medicinal cannabis biopharmaceutical (NTI164) improves symptoms of Rett Syndrome – a Phase I/II clinical trial', will be presented during the poster session on Monday 9 June from 5-7pm (US EST).

Professor Ellaway will then conduct an oral presentation, titled 'Full spectrum medicinal cannabis in Rett syndrome: Results of an open-label Phase 1/2 clinical trial' at 9:55am (US EST) Wednesday 11 June as part of the Industry Updates segment of the event.

For more information on the event, please visit: <https://www.rett syndrome.org/researchers/annual-rett-syndrome-scientific-meeting/>

This announcement has been authorised for release by the board of Neurotech International Limited.

For further information contact us via info@neurotechinternational.com

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety. In addition, Neurotech has completed and reported statistically significant and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. Neurotech has received human ethics committee clearance for a Phase I/II clinical trial in spastic cerebral palsy.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.

About NTI164

NTI164 is a proprietary drug formulation derived from unique cannabis strains with a novel combination of cannabinoids including CBDA, CBC, CBDP, CBDB and CBN. Clinical studies have demonstrated a potent anti-proliferative, anti-oxidative, anti-inflammatory and neuro-protective effects in human neuronal and microglial cells. NTI164 is being developed as a therapeutic drug product for a range of neurological disorders in children where neuroinflammation is involved.